By Editorial Staff
Published September 14, 2026
In the high-stakes arena of immuno-oncology, a paradigm shift may be underway. Summit Therapeutics and its partner Akeso have unveiled compelling new Phase 3 clinical data that position their experimental drug, ivonescimab, as a formidable successor to Merck & Co.’s industry-standard therapy, Keytruda. The results, presented at the World Conference on Lung Cancer in South Korea, have ignited intense debate on Wall Street regarding the future of lung cancer care and which therapeutic modality will ultimately inherit the market share currently commanded by the world’s best-selling drug.
Main Facts: The HARMONi-2 Breakthrough
The core of the excitement stems from the “HARMONi-2” clinical trial, a pivotal study designed to measure the efficacy of ivonescimab against the current standard of care for non-small cell lung cancer (NSCLC). Ivonescimab is a novel bispecific antibody engineered to target both PD-1 (a protein that inhibits immune response) and VEGF (a protein involved in tumor blood vessel formation). By hitting these two biological targets simultaneously, the drug aims to “unlock” the immune system while cutting off the tumor’s supply lines.
In the head-to-head trial, patients receiving ivonescimab demonstrated a significant survival advantage. The median overall survival (OS) for patients treated with ivonescimab reached 30.8 months, a marked improvement over the 22.6 months observed in the cohort treated with Merck’s Keytruda. This eight-month extension in median survival represents a 27% reduction in the relative risk of death, a figure that has captured the attention of oncologists and investors alike.
Perhaps more significant is the sub-group analysis involving patients whose tumors express high levels of PD-L1—the exact population for which Keytruda is currently the preferred monotherapy. In this critical cohort, ivonescimab reduced the relative risk of death by 42%, suggesting that the dual-action mechanism provides a robust benefit precisely where standard monotherapies are most commonly used.
Chronology: A Two-Year Journey of Scrutiny
The path to these results has been defined by skepticism and intense scientific validation.
- 2024: Akeso receives regulatory approval in China for ivonescimab in combination with chemotherapy for patients with EGFR-mutated NSCLC, following positive trends in overall survival.
- 2025: As Summit Therapeutics moves to integrate ivonescimab into global development pipelines, concerns emerge from international analysts. The primary criticism centers on the "China-only" data sets. Critics argued that the genetic profiles of the patient populations and the differences in standard-of-care practices in Chinese hospitals might not be representative of Western patients.
- Early 2026: The scientific community anxiously awaits the HARMONi-2 data, which was billed as the first late-stage trial capable of proving the superiority of a bispecific PD-1/VEGF approach over existing PD-1 inhibitors.
- September 2026: The data is officially presented at the World Conference on Lung Cancer. The publication of the 30.8-month median survival figure serves as a definitive turning point, shifting the conversation from "if" the drug works to "how well" it compares to emerging competitive technologies.
Supporting Data: Dissecting the Survival Benefit
The statistical significance of the HARMONi-2 trial cannot be understated. While progression-free survival (PFS) is a standard early indicator of a drug’s efficacy, overall survival is the "gold standard" in oncology. The fact that ivonescimab met this primary endpoint in a broad population provides a foundation for regulatory filings in the United States and Europe.
In the high-PD-L1 expression group, the 42% reduction in risk of death is particularly striking. By targeting the PD-L1/PD-1 axis while simultaneously inhibiting VEGF, ivonescimab effectively treats the tumor microenvironment with two distinct strategies. Researchers believe that the VEGF inhibition helps normalize the tumor vasculature, potentially allowing more immune cells to infiltrate the tumor, thereby enhancing the potency of the PD-1 blockade.
However, the medical community remains cautious. Analysts at TD Cowen, led by Tyler Van Buren, noted that these results "not only validate ivonescimab’s earlier PFS benefit but also strengthen confidence that a PD-1/VEGF bispecific can outperform PD-1 monotherapy on the endpoint that matters most to physicians." This sentiment reflects a growing consensus that the "bispecific" era of immunotherapy may be dawning.
Official Responses and Industry Outlook
The reception from the financial and medical sectors has been polarized.
The Bullish View:
Proponents argue that the results are a "clear win" for Summit and Akeso. By demonstrating a superiority in overall survival, they have successfully cleared the primary hurdle for global regulatory approval. If these findings are replicated in upcoming global Phase 3 trials, ivonescimab could potentially reset the standard of care for first-line lung cancer treatment.
The Skeptical View:
Not all analysts are convinced. Daina Graybosch of Leerink Partners has maintained a more cautious stance, highlighting the emergence of "Sac-TMT," an antibody-drug conjugate (ADC) developed by Merck in collaboration with China’s Kelun. In recent trials, Sac-TMT demonstrated a 45% reduction in the relative risk of death in a similar patient population.
Graybosch notes that the existence of such high-performing ADCs creates a genuine dilemma for the future of the market. "The HARMONI-2 data adds uncertainty on whether a ‘bio-better VEGF/PD-1’ or a ‘bio-better chemo’ is more likely to inherit Keytruda’s massive revenues," she stated in a recent client note. The industry is effectively split between two schools of thought: those who believe that modifying the immune checkpoint (bispecifics) is the future, and those who believe that more potent chemotherapy delivery (ADCs) will dominate.
Implications: The Post-Keytruda Era
The implications of the HARMONi-2 data extend far beyond the balance sheets of Summit and Akeso. Merck’s Keytruda has enjoyed a period of unprecedented dominance, serving as the backbone of therapy for dozens of cancer indications. The prospect of an "heir apparent" suggests that the lung cancer market—a multi-billion dollar segment—is poised for a period of rapid, disruptive innovation.
1. Regulatory Hurdles
For Summit and Akeso, the next phase will involve translating these findings into a successful New Drug Application (NDA) with the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). Regulators will be looking closely at the safety profile of the VEGF component, as VEGF inhibitors are historically associated with specific toxicities that the medical community will need to manage in a combination therapy.
2. Clinical Practice Shifts
If ivonescimab continues to show superior survival data, oncologists will face a choice. Will they abandon the trusted, well-understood safety profile of Keytruda for the superior survival efficacy of a bispecific agent? History suggests that if the survival delta remains at eight months or higher, the clinical shift could happen with significant speed.
3. The Competitive Landscape
Merck is not standing still. By investing in its own ADC pipeline (like Sac-TMT), the company is hedging its bets. If its own product eventually competes with its blockbuster Keytruda, it ensures that the company remains at the forefront of the lung cancer market regardless of which technological approach—bispecific or ADC—wins out.
As the industry moves toward 2027, all eyes will be on the ongoing global Phase 3 trials. The HARMONi-2 data has proven that the dual-action mechanism is more than a theoretical advantage; it is a clinical reality. Whether it will be enough to topple the giant remains the central question of the decade in oncology. For now, Summit and Akeso have done the one thing that matters most: they have given patients a fighting chance at a longer life.
About the Author
